Abstract
Abstract
Background: Inflammation is a recognized factor in cancer progression and resistance to treatment. Several studies correlated inflammation-related peripheral blood indices (PBI) to disease progression and poor survival in various cancers and different populations. Nonetheless, inflammation is affected by the distinctive characteristics and environmental exposure of each population. There is no prior study addressing the association of pre-treatment inflammatory markers with outcomes in patients with BC from Saudi Arabia. In this study, we evaluated post-treatment response of LABC in relation to inflammation-related PBI. Methods: We retrospectively analyzed the data of female patients with LABC undergoing neoadjuvant chemotherapy (NACT). Demographics, BMI, clinicopathologic characteristics and stage of the tumor, follow-up status and response to treatment were collected. Outcomes were evaluated in relation to pre-treatment PBI that were grouped based on the local laboratory cutoff values. Response rate (RR) and type was assessed according to post-NACT radiologic evaluation of the breast and subcategorized into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Results: A total of 172 female patients with BC met the eligibility criteria from January 2014 to December 2019. The mean age at diagnosis was 53±11, and BMI was 31±6. Left BC accounted for 55% and the majority was invasive ductal carcinoma in 85.5%, moderately differentiated in 51%, stage III (AJCC 8th edition) in 73%, and HR-positive tumor in 79%. HER2-positive BC was reported in 32% and TNBC in 10%. Radiologic (CR) accounted for the majority of RR (71.5%). A higher percentage of patients with normal red cell distribution width (RDW) and low neutrophil to lymphocyte ratio (NLR) had radiologic CR with a significant P-value of (0.003) and (0.014), respectively (Table 1). Conclusion: Among several peripheral blood indices, only RDW and NLR significantly influenced post-treatment response in this cohort. They can be explored further to potentially predict response after systemic therapy in patients with LABC. The great advantage of these biomarkers stems from their availability and affordability in routine clinical practice.
Table 1.Post-treatment response type & distribution according to inflammation-related peripheral blood indicesVariablesCR(N=123)PR(N=20)SD(N=23)PD(N=6)P valueN=172N(%)N(%)N(%)N(%)NLR High >322(81%)2(7%)0(0%)3(11%)0.014Low ≤3101(70%)18(12%)23(15%)3(2%)RDW High >14.122(92%)2(8%)0(0%)0(0%)0.003Normal 11-14.1100(69%)18(12%)23(16%)5(3%)Low <111(50%)0(0%)0(0%)1(50%)
Citation Format: Atlal Abusanad, Abdullah M Alghamdi, Ahmed M Saggaf, Tala Gazzaz, Rival Brika. The influence of pre-treatment peripheral blood inflammatory markers on post-treatment response in patients with locally advanced breast cancer (LABC) from Saudi Arabia [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-29.